中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

30 records (took 0.012 seconds)

    Process for preparing telmisartan
    1.
    发明授权
    Process for preparing telmisartan 失效
    替米沙坦制备方法

    公开(公告)号：US07501448B2

    公开(公告)日：2009-03-10

    申请号：US11250267

    申请日：2005-10-13

    Applicant: Nurit Perlman ,  Eyal Gilboa

    Inventor： Nurit Perlman ,  Eyal Gilboa

    IPC: A61K31/4184 ,  C07D235/04

    CPC classification number: C07D235/14 ,  C07D235/18

    Abstract: Provided are processes for preparing telmisartan alkyl ester and telmisartan using environmentally friendly organic solvents that are easily removed from the reaction mixture, wherein a telmisartan alkyl ester is isolated and hydrolyzed to form telmisartan or the telmisartan is prepared using a synthesis in a single reaction vessel.

    Abstract translation: 提供了使用易于从反应混合物中除去的环境友好的有机溶剂来制备替米沙坦烷基酯和替米沙坦的方法，其中分离并水解替米沙坦烷基酯以形成替米沙坦，或者在单个反应容器中使用合成制备替米沙坦。

    Process for preparing telmisartan
    2.
    发明申请
    Process for preparing telmisartan 审中-公开
    替米沙坦制备方法

    公开(公告)号：US20090124814A1

    公开(公告)日：2009-05-14

    申请号：US12319834

    申请日：2009-01-12

    Applicant: Nurit Perlman ,  Eyal Gilboa

    Inventor： Nurit Perlman ,  Eyal Gilboa

    IPC: C07D403/02

    CPC classification number: C07D235/14 ,  C07D235/18

    Abstract: Provided are processes for preparing telmisartan-alkyl ester and telmisartan using environmentally friendly organic solvents that are easily removed from the reaction mixture, wherein a telmisartan alkyl ester is isolated and hydrolyzed to form telmisartan or the telmisartan is prepared using a synthesis in a single reaction vessel.

    Abstract translation: 提供了使用易于从反应混合物中除去的环境友好的有机溶剂来制备替米沙坦 - 烷基酯和替米沙坦的方法，其中分离并水解替米沙坦烷基酯以形成替米沙坦，或者使用单个反应容器中的合成制备替米沙坦 。

    Amorphous and polymorphic forms of telmisartan sodium
    3.
    发明申请
    Amorphous and polymorphic forms of telmisartan sodium 审中-公开
    替米沙坦钠的无定形和多晶型

    公开(公告)号：US20060293377A1

    公开(公告)日：2006-12-28

    申请号：US11267520

    申请日：2005-11-03

    Applicant: Shlomit Wizel ,  Nurit Perlman ,  Sharon Avhar-Maydan ,  Eyal Gilboa

    Inventor： Shlomit Wizel ,  Nurit Perlman ,  Sharon Avhar-Maydan ,  Eyal Gilboa

    IPC: A61K31/4184 ,  C07D403/02

    CPC classification number: C07D235/20

    Abstract: Provided is the amorphous form of telmisartan sodium and the preparation thereof. Also provided are the telmisartan sodium polymorph crystal Forms 0 to XIII and XV to XX and preparations thereof. Also provided are pharmaceutical composition of amorphous and polymorphic forms of telmisartan sodium or mixtures thereof, and methods of treatment of a mammal in need thereof.

    Abstract translation: 提供替米沙坦钠的无定形形式及其制备方法。 还提供了替米沙坦钠多晶型晶型0至XIII和XV至XX及其制剂。 还提供了替米沙坦钠或其混合物的无定形和多晶型形式的药物组合物，以及治疗有需要的哺乳动物的方法。

    Process for preparing telmisartan
    5.
    发明申请
    Process for preparing telmisartan 失效

    公开(公告)号：US20060094883A1

    公开(公告)日：2006-05-04

    申请号：US11250267

    申请日：2005-10-13

    Applicant: Nurit Perlman ,  Eyal Gilboa

    Inventor： Nurit Perlman ,  Eyal Gilboa

    IPC: C07D403/02

    CPC classification number: C07D235/14 ,  C07D235/18

    Abstract: Provided are processes for preparing telmisartan alkyl ester and telmisartan using environmentally friendly organic solvents that are easily removed from the reaction mixture, wherein a telmisartan alkyl ester is isolated and hydrolyzed to form telmisartan or the telmisartan is prepared using a synthesis in a single reaction vessel.

    CRYSTALLINE FORMS OF SITAGLIPTIN PHOSPHATE
    10.
    发明申请
    CRYSTALLINE FORMS OF SITAGLIPTIN PHOSPHATE 审中-公开
    磷酸西他汀的结晶形式

    公开(公告)号：US20100041885A1

    公开(公告)日：2010-02-18

    申请号：US12410738

    申请日：2009-03-25

    Applicant: Nurit Perlman ,  Revital Ramaty ,  Mili Abramov ,  Nina Finkelstein ,  Eli Lancry ,  Shay Asis ,  Ariel Mittelman

    Inventor： Nurit Perlman ,  Revital Ramaty ,  Mili Abramov ,  Nina Finkelstein ,  Eli Lancry ,  Shay Asis ,  Ariel Mittelman

    IPC: C07D471/08

    CPC classification number: C07D487/04

    Abstract: A Sitagliptin phosphate characterized by data selected from the group consisting of: a powder XRD pattern with peaks at 4.7, 13.5, 17.7, 18.3, and 23.7±0.2 degrees two theta; a powder XRD pattern with peaks at about 4.7, 13.5, and 15.5±0.2 degrees two theta and at least another two peaks selected from the following list: 14.0, 14.4, 18.3, 19.2, 19.5 and 23.7±0.2 degrees two theta; and a powder XRD pattern with peaks at about 13.5, 19.2, and 19.5±0.2 degrees two theta and at least another two peaks selected from the following list: 4.7, 14.0, 15.1, 15.5, 18.3, and 18.7±0.2 degrees two theta; a powder XRD pattern with peaks at about 13.5, 15.5, 19.2, 23.7, and 24.4±0.2 degrees two theta; and a powder XRD pattern with peaks at about 4.65, 13.46, 17.63, 18.30, and 23.66±0.10 degrees two theta, processes for preparing said Sitagliptin crystalline form, and pharmaceutical compositions thereof, are provided.

    Abstract translation: 磷酸西他列汀，其特征在于选自以下的数据：粉末XRD图谱，其峰为4.7,13.5,17.7,18.3和23.7±0.2度2θ; 在约4.7,13.5和15.5±0.2度2θ处具有峰的粉末XRD图案和至少另外两个选自以下列表的峰：14.0,14.4,18.3,19.2,19.5和23.7±0.2度2θ; 和具有在约13.5,19.2和19.5±0.2度2θ处以及从下列列表中选择的至少另外两个峰的峰的粉末XRD图：4.7,14.0,15.1,15.5,18.3和18.7±0.2度2θ; 在约13.5,15.5,19.2,23.7和24.4±0.2度2θ处具有峰的粉末XRD图案; 并且提供了在约4.65,13.46,17.63,18.30和23.66±0.10度2θ处具有峰的粉末XRD图案，制备所述西格列汀结晶形式的方法及其药物组合物。

Patent Agency Ranking